Vasomedical Expands EECP Education To Clinicians Specializing In Diabetes; EECP Therapy Is Being Presented For The First Time At Two International Scientific Sessions This Summer

Business Wire, June 12, 2000

Business & Medical Editors

WESTBURY, N.Y.--(BUSINESS WIRE)--June 12, 2000

Vasomedical, Inc. (Nasdaq: VASO) announced today that EECP(R) therapy is being presented to diabetes specialists at two international venues this Summer: the 60th Scientific Sessions of the American Diabetes Association (ADA), scheduled for June 9-13 in San Antonio, and the 82nd annual meeting of The Endocrine Society (ENDO 2000), scheduled for June 21-24 in Toronto.

Vasomedical is exhibiting for the first time at the ADA, where EECP therapy is being presented to the approximately 7,500 attending diabetes researchers, physicians, and scientists as safe, effective treatment for angina in diabetic patients. Approximately 46% of EECP therapy patients have a history of diabetes and Type 2 diabetes is a predictor of cardiovascular disease, affecting more than 14 million patients in the United States alone.

Accepted for presentation at ENDO 2000 is, "Vascular endothelial growth factor (VEGF) and atrial natriuretic peptide (pro-ANP) in enhanced external counterpulsation", to be presented by Drs. S. Kho and H.E. Carlson of the State University of New York at Stony Brook. The study measures changes in blood levels of a specific growth factor and peptide in response to EECP therapy. Though not conclusive, the authors suggest that changes in the level of these factors may be one of the mechanisms of action to explain the positive clinical benefits seen in patients who have undergone enhanced external counterpulsation therapy. These include the reduction or elimination of angina symptoms through increased coronary perfusion and enhanced development of collateral circulation in both diabetic and non-diabetic patients.

Speaking about Vasomedical's presence at this year's ADA, Doug Goldman, Vice President of Marketing and Business Development commented, "It's been well documented that patients with Type 2 (non-insulin dependent) diabetes are at increased risk for developing coronary artery disease. We are starting to see increased evidence of the effectiveness of EECP therapy in addressing the symptoms of coronary artery disease earlier in the progression of the disease across a broad spectrum of patients, rather than as a no-options treatment limited to patients in the later stages of the disease."

The American Diabetes Association, with a membership of 20,000, is the nation's leading nonprofit health organization providing diabetes research, information and advocacy for diabetes patients. Founded in 1940, the ADA conducts programs in all 50 states.

The Endocrine Society membership of 9,000 includes diabetes specialists, internal medicine physicians, and endocrinologists; about 6,000 are expected to attend ENDO 2000.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California at San Diego, the University of California at San Francisco, State University of New York at Stony Brook and the University of Virginia. The company provides hospitals, clinics and private practices EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes.

Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.